Holy Name Medical Center only NJ Hospital to Receive

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Holy Name Medical Center only NJ Hospital to Receive Hepatitis Testing Award at White House

TEANECK, N.J., May 20, 2016 (GLOBE NEWSWIRE) -- Holy Name Medical Center's ongoing efforts to provide free viral hepatitis screening were recognized by the U.S. Department of Human Services (HHS). Acting Assistant Secretary for Health, Karen B. DeSalvo, MD, MPH, MSc, presented the Viral Hepatitis Recognition Award to Kyung Hee Choi, Holy Name's Vice President of Asian Health Services. The award was given during a special event, Responding to Viral Hepatitis in the U.S. – A National Hepatitis Testing Day Observance, on May 19, 2016 at 10 AM at the Eisenhower Executive Office Building in Washington, DC on the grounds of the White House. Holy Name is one of 12 recipients in the country, and the only organization in New Jersey to receive this award.

An estimated 3.4 million to 5.3 million people are living with viral hepatitis in the U.S., many of whom do not know they are infected. Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection can lead to serious liver disease, liver cancer, and death if undiagnosed and untreated.

Holy Name was among other organizations selected by state and national viral hepatitis prevention coordinators and advocates after documenting success in screening hard-to-reach populations. They ensured a full diagnostic workup, linked persons identified as being chronically infected into care, and tracked data on program activities.

Holy Name offers free hepatitis C testing through the emergency department for baby boomers, anyone born between 1945 and 1965. The hepatitis C virus is prevalent among this population, for reasons not quite understood, and Holy Name is using a grant from Gilead Sciences to fund the screenings. It is the only Bergen County hospital providing the free testing.

Holy Name also provides free screenings for hepatitis B. The hospital's Asian Health Services is using grants from various organizations for the testing, focusing on the Asian American population where the disease is so prevalent.

"Holy Name has become a national model for delivering culturally-appropriate care and part of that mission is knowing the specific needs of our diverse communities," said Michael Maron, President and CEO of Holy Name. "We are proud to be recognized by the White House and HHS for our committed efforts to offer education, screenings and treatment for viral hepatitis."

Accepting the award with Ms. Choi was J. Cedar Wang, MSN, RN, CHSE, Director of Simulation Education at Holy Name. The Simulation Center is instrumental in helping train Holy Name employees and volunteers on culturally-sensitive care and to be cognizant of specific diseases that are more common in different populations.

"Asian Americans have the highest prevalence rate of viral hepatitis B among all ethnicities in our region and having the screenings is the first step in achieving early detection and preventive care for this community," said Ms. Choi.

Nearly one out of every 20 Americans is infected with the hepatitis B virus, which is transmitted through blood and bodily fluids, often from mother to child during childbirth. But the virus is much more common in members of the Asian community: Asian Americans are at least 10 times more likely to have or develop hepatitis B than Caucasians. In an attempt to reach a large number of people within the Asian-American community, staff members and volunteers of the Asian Health Services are organizing screenings at community churches. Hepatitis B screenings and vaccines are also available at the hospital's Teaneck campus.

"Despite a number of important advances in viral hepatitis testing, care, and treatment in recent years, awareness of HBV and HCV remain unfortunately low among both affected populations and healthcare providers," observed Corinna Dan, R.N., M.P.H., Viral Hepatitis Policy Advisor in the HHS Office of HIV/AIDS and Infectious Disease Policy. "That's why it is vitally important for all stakeholders – federal and nonfederal alike – to make the most of opportunities like Hepatitis Awareness Month and Hepatitis Testing Day to educate as many people as possible. These efforts will help us achieve the U.S. Viral Hepatitis Action Plan's [PDF 2.05 MB] goals of increasing the proportion of people living with HBV and HCV aware of their infection so they can take steps to protect their health and prevent transmission to others."

Many people with the virus do not experience symptoms and don't know they are infected. Those who do have symptoms may have yellowing of the skin and eyes, dark urine, extreme fatigue, nausea, vomiting and abdominal pain.

When left untreated, 25 percent of those carrying the virus will develop a chronic liver infection, cirrhosis of the liver or liver failure that can result in death. Treatment can stop the progression of the acute disease and chronic hepatitis B infection can be successfully treated with drugs.

The most effective way to prevent the hepatitis B infection is with vaccination. Financial subsidies for vaccines are available for those with low incomes.

#####

ABOUT HOLY NAME MEDICAL CENTER

Holy Name Medical Center is a fully accredited, not-for-profit healthcare facility based in Teaneck, New Jersey. Founded and sponsored by the Sisters of St. Joseph of Peace in 1925, the comprehensive 361-bed medical center offers leading-edge medical practice and technology administered in an environment rooted in a tradition of compassion and respect for every patient. Holy Name provides high quality health care across a continuum that encompasses education, prevention, early intervention, comprehensive treatment options, rehabilitation and wellness maintenance. To learn more, visit HolyName.org.

Katherine Emmanouilidis Director, Public Relations & Marketing Holy Name Medical Center 718 Teaneck Road | Teaneck, NJ 07666 Tel: 201-227-6047

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 350

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 342

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 182

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading

Top 5 Most Recently Viewed Articles

HALiXPEDITE Revolutionizes Biologics Therapy Development Process

Updated Category News Views 147

HALiXPEDITE: Transforming the Future of Biologics Development HALIX, a prominent global healthcare Contract Development and Manufacturing Organization (CDMO), recently unveiled its innovative platform, HALiXPEDITE, at a notable conference. This platform is specifically designed to expedite the development of biologics therapies, focusing on a streamlined approach to...

Continue Reading
Day One Biopharmaceuticals to Share Q3 2025 Insights

Updated Category News Views 170

Day One Biopharmaceuticals to Present Q3 2025 Financial Results In a busy season for the biopharmaceutical industry, Day One Biopharmaceuticals (Nasdaq: DAWN) has announced it will host a live conference call and webcast aimed at reporting its financial results and outlining corporate progress for the third quarter of 2025. Conference Call Details The event is scheduled...

Continue Reading
Leica Biosystems Promotes DICOM Standards for Digital Pathology

Updated Category News Views 114

Leica Biosystems Promotes DICOM Standards for Digital Pathology Leica Biosystems, a prominent figure in anatomic pathology, has recently made waves in the medical field with a bold new initiative. By announcing the non-enforcement of their Digital Pathology DICOM (Digital Imaging and Communications in Medicine) patent portfolio, they aim to boost the implementation of...

Continue Reading
LYNPARZA: A Breakthrough in Early Breast Cancer Treatments

Updated Category News Views 288

Significant Survival Benefits with LYNPARZA in Breast Cancer Recent findings from the OlympiA Phase III trial bring exciting news for patients battling early breast cancer. AstraZeneca and Merck & Co., Inc.'s LYNPARZA (olaparib) has showcased profound improvements in survival rates among patients with germline BRCA-mutated HER2-negative high-risk early breast cancer. This...

Continue Reading
EuroDry Limited's Stock Experiences Volatility Amid Challenges

Updated Category News Views 229

EuroDry Limited Faces Stock Turmoil EuroDry Ltd. (NASDAQ: EDRY), a leading provider in drybulk shipping, has recently encountered a tumultuous phase, with its stock reaching a noteworthy low at $14.1. This decline marks a significant reflection on the year's challenges the company has faced, indicated by a -14.71% change over the past year. Market Conditions and...

Continue Reading